SHL.DE · GER DAX

Siemens Healthineers AG

Healthcare · Medical Devices

€42.73 −€0.21 (−0.49%) today

Today's session · updated Nov 11, 2026, 13:57 · Source: Yahoo Finance

Consensus of 20 analysts

Buy

Median price target €47.00 +10.0%

Open: €42.97
Day range: 42.72 – €43.43
52-week range: 32.81 – €47.26
Volume: 387,105
Market cap: €47,823M
P/E (TTM): 21.8x
EPS (TTM): €1.96
EPS est. FY 2027: €2.34
P/E est. FY 2027: 18.3x
Dividend yield: 2.3%
Beta: 0.89
Payout: 51%

Analyst summary

Generated with AI · Nov 11, 2026, 15:05

Siemens Healthineers supplies diagnostic and therapeutic equipment, software and services across imaging, diagnostics, cancer care and advanced therapies. Q3 2026 revenue was €6,784M, with net income of €589M and EPS of €0.690. The shares trade at 21.8x trailing earnings, while consensus expects EPS to ease in FY 2027 before rising in FY 2028. Analysts’ median target implies 10.0% upside, and the dividend yield is 2.3%.

1Q3 2026 revenue reached €6,784M and net income was €589M.
2The 21.8x trailing P/E compares with forward P/Es of 18.3x for FY 2027 and 16.2x for FY 2028.
3Analysts’ median target of €47.00 implies +10.0% potential; 13 of 20 analysts rate the shares Buy.

Siemens Healthineers financials

Q3 2026 results, quarter ended Sep 30, 2026

Metric	Q3 2026	1-year change
Total revenue	€6,784M	n/a
Net income	€589M	n/a
Earnings per share	€0.53	n/a
Net margin	8.7%	n/a
Free cash flow	€703M	n/a
Debt / equity	0.04	n/a

Revenue and net income (€M)

Total revenueNet income

Quarter	Total revenue	Net income
Q2 2025	€5,662M	€552M
Q4 2025	€5,402M	€449M
Q1 2026	€5,680M	€506M
Q2 2026	€5,764M	€669M
Q3 2026	€6,784M	€589M

Q3 2026 revenue was €6,784M, net income €589M and net margin 8.7%; year-on-year comparisons are n/a. Across the reported sequence, revenue rose from €5,402M in Q4 2025 to €6,784M in Q3 2026, though net income eased from €669M in Q2 2026 to €589M. Annual EPS recovered from €1.340 in FY 2023 to €2.420 in FY 2026. Consensus anticipates a 3.3% decline to €2.339 in FY 2027, followed by 12.8% growth to €2.639 in FY 2028.

Reported quarterly EPS beat estimates in each quarter with a comparison supplied: by 11.1% in Q4 2025, 4.8% in Q1 2026, 33.1% in Q2 2026 and 2.8% in Q3 2026. Q3 free cash flow was €703M and debt/equity 0.04. The current P/E is 21.8x, against estimated forward P/Es of 18.3x for FY 2027 and 16.2x for FY 2028.

Written by AI · Nov 11, 2026, 15:05

Siemens Healthineers earnings per share (EPS)

Consensus estimates

Period	EPS est.	1-year change
Current quarterQ4 2026 · Analysts: 3	€0.5010.49 – 0.51	+2.2%€0.490
Next quarterQ1 2027 · Analysts: 3	€0.5700.54 – 0.61	+7.5%€0.530
Current yearFY 2027 · Analysts: 19	€2.3392.26 – 2.40	−3.3%€2.420
Next yearFY 2028 · Analysts: 18	€2.6392.37 – 2.81	+12.8%€2.339

Forward P/E: 18.3x (FY 2027) and 16.2x (FY 2028) at the current price.

Actual and estimated EPS (€)

Actual EPSEstimated EPS

Quarter	Actual EPS	Estimated EPS
Q2 2025	€0.490	—
Q4 2025	€0.490	€0.441
Q1 2026	€0.530	€0.506
Q2 2026	€0.700	€0.526
Q3 2026	€0.690	€0.671
Q4 2026	—	€0.501
Q1 2027	—	€0.570

Year	Actual EPS	Estimated EPS
FY 2022	€1.810	—
FY 2023	€1.340	—
FY 2024	€1.730	—
FY 2025	€1.910	—
FY 2026	€2.420	—
FY 2027	—	€2.339
FY 2028	—	€2.639

EPS trend

Quarter	EPS	YoY change
Q1 2027Estimated	€0.570	+7.5%
Q4 2026Estimated	€0.501	+2.2%
Q3 2026	€0.690est. €0.671 · surprise +2.8%	n/a
Q2 2026	€0.700est. €0.526 · surprise +33.1%	+42.9%
Q1 2026	€0.530est. €0.506 · surprise +4.8%	n/a
Q4 2025	€0.490est. €0.441 · surprise +11.1%	n/a
Q2 2025	€0.490	n/a

Year	EPS	Annual change
FY 2028Estimated	€2.639	+12.8%
FY 2027Estimated	€2.339	−3.3%
FY 2026	€2.420	+26.7%
FY 2025	€1.910	+10.4%
FY 2024	€1.730	+29.1%
FY 2023	€1.340	−26.0%
FY 2022	€1.810	n/a

Normalised EPS according to the analyst consensus collected by Yahoo Finance; it may differ from the reported EPS in the results table.

Siemens Healthineers dividend

Yield and payments

Dividend yield (TTM)	2.3%
Forward yield (next 12m)	2.3%
Dividend per share (TTM)	€1.00
Forward dividend (next 12m)	€1.00
Payout (TTM)	51%
Last dividend	€1.00Feb 6, 2026
Next ex-dividend date	n/a

Dividend per share by year (€)

PaidEstimated

Year	Dividend per share
2019	€0.70
2020	€0.80
2021	€0.80
2022	€0.85
2023	€0.95
2024	€0.95
2025	€0.95
est. 12m	€1.00

The trailing dividend is €1.00 per share, giving a 2.3% yield; the estimated forward dividend is also €1.00, with a 2.3% yield. The payout ratio is 51%. The dividend has risen from €0.70 in 2019 to €0.95 in 2023, remained at €0.95 through 2025, and is estimated at €1.00 over the next 12 months.

The latest recorded ex-dividend date was Feb 6, 2026, for a €1.00 payment. The next ex-date is n/d, so no upcoming date is available in the supplied data. The yield and payout indicate a material shareholder return, while the forward dividend estimate suggests the current payment level is expected to continue.

Written by AI · Nov 11, 2026, 15:05

Siemens Healthineers forecasts

20 analyst ratings

Buy65% Hold35% Sell0%

Consensus: Buy · 13 buy, 7 hold, 0 sell

1-year price forecast

Share price Price target (high, median, low)

12-month price targets
Target	Price	Upside
High	€57.40	+34.3%
Median	€47.00	+10.0%
Low	€37.00	−13.4%

Monthly close (last 12 months)
Date	Close
Nov 28, 2025	€42.84
Dec 30, 2025	€44.92
Jan 30, 2026	€42.17
Feb 27, 2026	€42.14
Mar 31, 2026	€36.30
Apr 30, 2026	€34.88
May 29, 2026	€34.92
Jun 30, 2026	€34.20
Jul 31, 2026	€36.86
Aug 31, 2026	€39.13
Sep 30, 2026	€37.97
Oct 30, 2026	€42.89
Nov 11, 2026	€42.73

Analyst sentiment is positive: 13 of 20 analysts (65%) rate the shares Buy, seven (35%) Hold and none Sell. The consensus rating is Buy. The median price target is €47.00, implying +10.0% upside from the quoted share price.

Target dispersion is meaningful: the high is €57.40 (+34.3%), while the low is €37.00 (−13.4%). EPS estimates point to a softer FY 2027, at €2.339 (−3.3%), followed by €2.639 (+12.8%) in FY 2028. That projected recovery supports the positive consensus, although the range of targets and near-term EPS decline argue for a measured reading.

Written by AI · Nov 11, 2026, 15:05

Siemens Healthineers peers

Ticker	Company	Market cap (€M)	P/E	Price (€)	1-day change	52-week range
SHL.DE	Siemens Healthineers	47,823	21.8x	42.73	−0.49%	32.8147.26
ABT	Abbott Laboratories	191,310	41.2x	110.46 $	−0.05%	81.97132.03
MDT	Medtronic	129,948	25.0x	101.59 $	−1.17%	73.31106.33
SYK	Stryker	123,454	34.5x	324.29 $	−0.44%	267.00389.33
BSX	Boston Scientific	64,791	18.9x	44.70 $	+1.54%	39.57105.65
EW	Edwards Lifesciences	59,806	60.5x	104.01 $	−0.67%	74.66105.37

Stocks quoted in another currency are shown in their trading currency.

Siemens Healthineers has a market capitalisation of €47,823M and a trailing P/E of 21.8x. Among the listed peers, Boston Scientific is valued at $64,791M with an 18.9x P/E, while Edwards Lifesciences has a $59,806M market capitalisation and a 60.5x P/E.

Abbott Laboratories, Medtronic and Stryker are larger by reported market capitalisation, at $191,310M, $129,948M and $123,454M respectively; their P/Es are 41.2x, 25.0x and 34.5x. Siemens Healthineers’ P/E is below those three, but above Boston Scientific’s.

Written by AI · Nov 11, 2026, 15:05

Risks, catalysts and conclusion

Generated with AI · Nov 11, 2026, 15:05

Risks

Hospital or provider investment delays could weigh on demand for imaging, diagnostic and therapeutic equipment.
Competitive pressure across medical devices could constrain pricing and reduce profitability.
If projected FY 2028 EPS growth fails to materialise, the current 21.8x P/E may be harder to sustain.

Catalysts

A recovery in FY 2028 EPS towards the €2.639 consensus estimate could support the shares.
Stronger demand for imaging and diagnostic systems could lift sales across the company’s healthcare-provider customer base.
Growth in Varian cancer-care services and Advanced Therapies products could broaden contribution beyond imaging.

Conclusion

Siemens Healthineers combines a broad medical-device portfolio with recent quarterly EPS beats and a low reported debt/equity ratio. The valuation is below several listed peers, while forward earnings estimates imply a lower P/E; however, consensus expects EPS to decline in FY 2027 before recovering in FY 2028. A 2.3% dividend yield adds income, but the target range and near-term earnings outlook support a balanced rather than unqualified positive assessment.

Analysis written automatically by AI from Yahoo Finance market data on Nov 11, 2026, 15:05.

This content is for information only and is not financial advice or a recommendation to buy or sell securities. Ratings and price targets come from third-party analysts. Investing in the stock market involves the risk of losing capital.

Siemens Healthineers AG

Analyst summary

Siemens Healthineers financials

Q3 2026 results, quarter ended Sep 30, 2026

Revenue and net income (€M)

Siemens Healthineers earnings per share (EPS)

Consensus estimates

Actual and estimated EPS (€)

EPS trend

Siemens Healthineers dividend

Yield and payments

Dividend per share by year (€)

Siemens Healthineers forecasts

20 analyst ratings

1-year price forecast

Siemens Healthineers peers

Risks, catalysts and conclusion

Risks

Catalysts

Conclusion

What the AI agents think about Siemens Healthineers

More companies in Healthcare

More DAX companies